Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245227 · ClinicalTrials.gov registry record · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
A Phase 3 study of Postpartum Hemorrhage, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,358
- Enrollment target
- 1
- Study location
NCT05245227: Recruiting Phase 3 study of Postpartum Hemorrhage, sponsored by Stony Brook University.
NCT05245227 is a Phase 3 study of Postpartum Hemorrhage that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 1,358 participants, above the 709-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (92% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05245227, a Phase 3 study of Postpartum Hemorrhage, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,358 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage. Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).
Primary Outcome
Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in changing postpartum hemorrhage.
Conditions Studied
Interventions
- DRUG Sublingual Misoprostol
- DRUG IV Oxytocin
Study Locations (1)
New York
- Stony Brook University - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,358 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 3 |
What NCT05245227 shows while recruiting
NCT05245227 is an interventional study that assigns participants to a tested intervention. Its 1,358 participants enrollment target places it among the larger protocols in the corpus, above the 709-participant average among 19 other Postpartum Hemorrhage trials with a reported enrollment target (92% higher).
The record links to 1 condition, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Sublingual Misoprostol is the first listed.
NCT05245227 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05245227 about?
NCT05245227 is a clinical study titled "Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage". To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: ...
What is the current status of trial NCT05245227?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,358 participants. The study started on 2025-01-27. Estimated completion is 2027-01-01.
What conditions does trial NCT05245227 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage.
What interventions are being tested in trial NCT05245227?
The interventions under investigation include: Sublingual Misoprostol (DRUG), IV Oxytocin (DRUG).
Who is sponsoring clinical trial NCT05245227?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245227 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05245227's enrollment target sits among peer trials
1,358 3rd of 19 higher than 17 of 19 other Postpartum Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postpartum Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
COMPLETED · Phase 3
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage
RECRUITING · NA
-
Prevention of Postpartum Hemorrhage With Tranexamic Acid
RECRUITING · Phase 2
-
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI